MoonLake Immunotherapeutics (MLTX) reported a Q4 loss Wednesday of $0.72 per diluted share, compared with a loss of $0.12 a year earlier.
Analysts polled by FactSet expected a loss of $0.62.
The company said it held cash, cash equivalents and short-term marketable debt securities of $448 million at the end of last year, compared with $493.9 million as of Sept. 30.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.